O	0	10	Randomized
O	11	16	trial
O	17	19	of
B-intervention	20	31	fenretinide
O	32	34	to
O	35	42	prevent
B-condition	43	49	second
I-condition	50	56	breast
I-condition	57	67	malignancy
O	68	70	in
O	71	76	women
O	77	81	with
O	82	87	early
O	88	94	breast
O	95	101	cancer
O	101	102	.

O	103	114	Fenretinide
O	114	115	,
O	116	117	a
O	118	125	vitamin
O	126	127	A
O	128	136	analogue
O	136	137	,
O	138	141	has
O	142	146	been
O	147	152	shown
O	153	155	to
O	156	163	inhibit
O	164	170	breast
O	171	185	carcinogenesis
O	186	188	in
O	189	200	preclinical
O	201	208	studies
O	208	209	.

O	210	212	We
O	213	223	determined
O	224	227	the
O	228	236	efficacy
O	237	239	of
O	240	251	fenretinide
O	252	254	in
O	255	265	preventing
O	266	267	a
O	268	274	second
O	275	281	breast
O	282	292	malignancy
O	293	295	in
O	296	301	women
O	302	306	with
O	307	313	breast
O	314	320	cancer
O	320	321	.

O	322	324	We
O	325	333	randomly
O	334	342	assigned
B-total-participants	343	347	2972
O	348	353	women
O	353	354	,
O	355	359	aged
B-age	360	362	30
I-age	362	363	-
I-age	363	365	70
I-age	366	371	years
O	371	372	,
B-eligibility	373	377	with
I-eligibility	378	388	surgically
I-eligibility	389	396	removed
I-eligibility	397	402	stage
I-eligibility	403	404	I
I-eligibility	405	411	breast
I-eligibility	412	418	cancer
I-eligibility	419	421	or
I-eligibility	422	428	ductal
I-eligibility	429	438	carcinoma
I-eligibility	439	441	in
I-eligibility	442	446	situ
O	447	449	to
O	450	457	receive
O	458	461	for
O	462	463	5
O	464	469	years
O	470	476	either
O	477	488	fenretinide
O	489	495	orally
O	496	497	(
O	497	500	200
O	501	503	mg
O	503	504	/
O	504	507	day
O	507	508	)
O	509	511	or
B-control	512	514	no
I-control	515	524	treatment
O	524	525	.

O	526	529	The
O	530	537	primary
O	538	541	end
O	542	547	point
O	548	551	was
O	552	555	the
B-outcome-Measure	556	565	incidence
I-outcome-Measure	566	568	of
I-outcome-Measure	569	582	contralateral
I-outcome-Measure	583	589	breast
I-outcome-Measure	590	596	cancer
I-outcome-Measure	597	599	or
I-outcome-Measure	600	611	ipsilateral
I-outcome-Measure	612	618	breast
I-outcome-Measure	619	625	cancer
O	626	627	7
O	628	633	years
O	634	639	after
O	640	653	randomization
O	653	654	.

O	655	660	Other
O	661	664	end
O	665	671	points
O	672	682	considered
O	683	687	post
O	688	691	hoc
O	692	696	were
O	697	700	the
O	701	705	same
O	706	714	outcomes
O	715	725	stratified
O	726	728	by
B-outcome-Measure	729	739	menopausal
I-outcome-Measure	740	746	status
O	746	747	,
B-outcome-Measure	748	757	incidence
I-outcome-Measure	758	760	of
I-outcome-Measure	761	768	distant
I-outcome-Measure	769	779	metastases
O	779	780	,
B-outcome-Measure	781	788	overall
I-outcome-Measure	789	798	mortality
O	798	799	,
O	800	803	and
B-outcome-Measure	804	810	tumors
I-outcome-Measure	811	813	in
I-outcome-Measure	814	819	other
I-outcome-Measure	820	826	organs
O	826	827	.

O	828	831	The
O	832	839	hazards
O	840	842	of
O	843	849	breast
O	850	856	cancer
O	857	867	occurrence
O	868	872	were
O	873	883	determined
O	884	886	by
O	887	890	Cox
O	891	903	proportional
O	904	911	hazards
O	912	922	regression
O	923	931	analysis
O	931	932	.

O	933	944	Statistical
O	945	950	tests
O	951	955	were
O	956	959	two
O	959	960	-
O	960	965	sided
O	965	966	.

O	967	969	At
O	970	971	a
O	972	978	median
O	979	990	observation
O	991	995	time
O	996	998	of
O	999	1001	97
O	1002	1008	months
O	1008	1009	,
O	1010	1015	there
O	1016	1020	were
O	1021	1023	no
O	1024	1037	statistically
O	1038	1049	significant
O	1050	1061	differences
O	1062	1064	in
O	1065	1068	the
B-outcome	1069	1079	occurrence
I-outcome	1080	1082	of
I-outcome	1083	1096	contralateral
I-outcome	1097	1103	breast
I-outcome	1104	1110	cancer
O	1111	1112	(
O	1112	1113	P
O	1114	1115	=
O	1115	1116	.
O	1116	1119	642
O	1119	1120	)
O	1121	1123	or
B-outcome	1124	1135	ipsilateral
I-outcome	1136	1142	breast
I-outcome	1143	1149	cancer
O	1150	1151	(
O	1151	1152	P
O	1153	1154	=
O	1154	1155	.
O	1155	1158	177
O	1158	1159	)
O	1160	1167	between
O	1168	1171	the
O	1172	1175	two
O	1176	1180	arms
O	1180	1181	.

O	1182	1189	However
O	1189	1190	,
O	1191	1193	an
O	1194	1205	interaction
O	1206	1209	was
O	1210	1218	detected
O	1219	1226	between
O	1227	1238	fenretinide
O	1239	1248	treatment
O	1249	1252	and
O	1253	1263	menopausal
O	1264	1270	status
O	1271	1273	in
O	1274	1278	both
O	1279	1287	outcomes
O	1288	1289	(
O	1289	1290	P
O	1291	1294	for
O	1295	1306	interaction
O	1307	1309	in
O	1310	1314	both
O	1315	1323	outcomes
O	1324	1325	=
O	1325	1326	.
O	1326	1329	045
O	1329	1330	)
O	1330	1331	,
O	1332	1336	with
O	1337	1338	a
O	1339	1347	possible
O	1348	1358	beneficial
O	1359	1365	effect
O	1366	1368	in
B-outcome	1369	1382	premenopausal
I-outcome	1383	1388	women
O	1389	1390	(
B-outcome	1390	1403	contralateral
I-outcome	1404	1410	breast
I-outcome	1411	1417	cancer
O	1417	1418	:
O	1419	1427	adjusted
O	1428	1434	hazard
O	1435	1440	ratio
O	1441	1442	[
O	1442	1444	HR
O	1444	1445	]
O	1446	1447	=
O	1448	1449	0
O	1449	1450	.
O	1450	1452	66
O	1452	1453	,
O	1454	1457	and
O	1458	1460	95
O	1460	1461	%
O	1462	1472	confidence
O	1473	1481	interval
O	1482	1483	[
O	1483	1485	CI
O	1485	1486	]
O	1487	1488	=
O	1489	1490	0
O	1490	1491	.
O	1491	1493	41
O	1493	1494	-
O	1494	1495	1
O	1495	1496	.
O	1496	1498	07
O	1498	1499	;
B-outcome	1500	1511	ipsilateral
I-outcome	1512	1518	breast
I-outcome	1519	1525	cancer
O	1525	1526	:
O	1527	1535	adjusted
O	1536	1538	HR
O	1539	1540	=
O	1541	1542	0
O	1542	1543	.
O	1543	1545	65
O	1545	1546	,
O	1547	1550	and
O	1551	1553	95
O	1553	1554	%
O	1555	1557	CI
O	1558	1559	=
O	1560	1561	0
O	1561	1562	.
O	1562	1564	46
O	1564	1565	-
O	1565	1566	0
O	1566	1567	.
O	1568	1570	92
O	1570	1571	)
O	1572	1575	and
O	1576	1578	an
O	1579	1587	opposite
O	1588	1594	effect
O	1595	1597	in
B-outcome	1598	1612	postmenopausal
I-outcome	1613	1618	women
O	1619	1620	(
B-outcome	1620	1633	contralateral
I-outcome	1634	1640	breast
I-outcome	1641	1647	cancer
O	1647	1648	:
O	1649	1657	adjusted
O	1658	1660	HR
O	1661	1662	=
O	1663	1664	1
O	1664	1665	.
O	1665	1667	32
O	1667	1668	,
O	1669	1672	and
O	1673	1675	95
O	1675	1676	%
O	1677	1679	CI
O	1680	1681	=
O	1682	1683	0
O	1683	1684	.
O	1684	1686	82
O	1686	1687	-
O	1687	1688	2
O	1688	1689	.
O	1689	1691	15
O	1691	1692	;
B-outcome	1693	1704	ipsilateral
I-outcome	1705	1711	breast
I-outcome	1712	1718	cancer
O	1718	1719	:
O	1720	1728	adjusted
O	1729	1731	HR
O	1732	1733	=
O	1734	1735	1
O	1735	1736	.
O	1736	1738	19
O	1738	1739	,
O	1740	1743	and
O	1744	1746	95
O	1746	1747	%
O	1748	1750	CI
O	1751	1752	=
O	1753	1754	0
O	1754	1755	.
O	1755	1757	75
O	1757	1758	-
O	1758	1759	1
O	1759	1760	.
O	1761	1763	89
O	1763	1764	)
O	1764	1765	.

O	1766	1771	There
O	1772	1776	were
O	1777	1779	no
O	1780	1793	statistically
O	1794	1805	significant
O	1806	1817	differences
O	1818	1825	between
O	1826	1829	the
O	1830	1833	two
O	1834	1838	arms
O	1839	1841	in
B-outcome	1842	1848	tumors
I-outcome	1849	1851	in
I-outcome	1852	1857	other
I-outcome	1858	1864	organs
O	1864	1865	,
B-outcome	1866	1875	incidence
I-outcome	1876	1878	of
I-outcome	1879	1886	distant
I-outcome	1887	1897	metastasis
O	1897	1898	,
O	1899	1902	and
B-outcome	1903	1906	all
I-outcome	1906	1907	-
I-outcome	1907	1912	cause
I-outcome	1913	1922	mortality
O	1922	1923	.

O	1924	1935	Fenretinide
O	1936	1945	treatment
O	1946	1948	of
O	1949	1954	women
O	1955	1959	with
O	1960	1966	breast
O	1967	1973	cancer
O	1974	1977	for
O	1978	1979	5
O	1980	1985	years
O	1986	1993	appears
O	1994	1996	to
O	1997	2001	have
O	2002	2004	no
O	2005	2018	statistically
O	2019	2030	significant
O	2031	2037	effect
O	2038	2040	on
O	2041	2044	the
O	2045	2054	incidence
O	2055	2057	of
O	2058	2064	second
O	2065	2071	breast
O	2072	2084	malignancies
O	2085	2092	overall
O	2092	2093	,
O	2094	2102	although
O	2103	2104	a
O	2105	2113	possible
O	2114	2121	benefit
O	2122	2125	was
O	2126	2134	detected
O	2135	2137	in
O	2138	2151	premenopausal
O	2152	2157	women
O	2157	2158	.

O	2159	2164	These
O	2165	2172	studies
O	2172	2173	,
O	2174	2186	particularly
O	2187	2190	the
O	2191	2195	post
O	2196	2199	hoc
O	2200	2208	analyses
O	2208	2209	,
O	2210	2213	are
O	2214	2224	considered
O	2225	2236	exploratory
O	2237	2240	and
O	2241	2245	need
O	2246	2248	to
O	2249	2251	be
O	2252	2261	confirmed
O	2261	2262	.
